
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BANK1 CRISPR/Cas9 KO Plasmid (h) | sc-405620 | 20 µg | $397.00 |
BANK1 (B-cell scaffold protein with ankyrin repeats 1) is a B lymphocyte–enriched adaptor protein that integrates signaling downstream of the B cell antigen receptor and innate immune receptors to shape activation, calcium mobilization, and transcriptional outputs. Through scaffold-mediated assembly of signaling complexes, BANK1 influences pathways linked to NF-κB and MAPK signaling and can modulate cytokine responses and B cell differentiation programs. Genetic and expression studies associate BANK1 with immune dysregulation and susceptibility to autoimmune phenotypes, including systemic lupus erythematosus, supporting its relevance to inflammatory signaling networks. As a regulator of B cell signaling architecture, BANK1 is frequently studied in contexts such as antigen-driven activation, tolerance checkpoints, and cross-talk with interferon-related responses.
BANK1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BANK1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BANK1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BANK1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BANK1 protein expression.
This CRISPR knockout system enables efficient generation of BANK1-deficient cell models for investigation of BANK1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.